upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
ascophen p tabletes
vip pharma eesti ou, estonia - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete
citramon p tabletes
stada arzneimittel ag, germany - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete
ol-askofēns tabletes
olainfarm, as, latvija - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete
hjertemagnyl 150 mg/21 mg apvalkotās tabletes
orifarm healthcare a/s, denmark - skābes acetylsalicylicum, magnija oxidum - apvalkotā tablete - 150 mg/21 mg
hjertemagnyl 75 mg/10,5 mg apvalkotās tabletes
orifarm healthcare a/s, denmark - skābes acetylsalicylicum, magnija oxidum - apvalkotā tablete - 75 mg/10,5 mg
citramons forte tabletes
stirolbiofarm baltikum, sia, latvia - kofeīns, paracetamolum, skābes acetylsalicylicum - tablete
ol-citramons tabletes
olainfarm, as, latvija - paracetamolum, skābes acetylsalicylicum, kofeīns - tablete
ubichinon compositum šķīdums injekcijām
biologische heilmittel heel gmbh, germany - ubidecarenonum, skābes ascorbicum, thiaminum hydrochloricum, nātrija riboflavinum phosphoricum, pyridoxinum hydrochloricum, nicotinamidum, rudens vēlziede (colchicum autumnale, podophyllum peltatum, conium plankumainas, hydrastis kanādas, skābes l-lacticum, hydrochinonum, skābes dl alfa-liponicum, sēru, manganum phosphoricum, nātrija diethyloxalaceticum, trichinoylum, naphthochinonum, para-benzochinonum, adenosinum triphosphoricum, coenzymum bija aparine, skābes acetylsalicylicum, histaminum, nadidum, magnija gluconicum, anthrachinonum, melleņu myrtillus - Šķīdums injekcijām
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.